TP53 and neoplasm: According to Liu et al. (2015) (166), the interleukin-6 (IL-6)/JAK2/STAT pathway may downregulate P53 and P21 expression, which could increase tumor initiation, upregulate DNMT1, and encourage the growth of lung CSCs.